|Market Cap||Dividend Yield (Annualized)|
|0.0125L 0.013 H|
|52 WEEK HIGH LOW|
|0.008L 0.034 H|
|52 W H/L||0.034/0.008|
|NPAT After Abnormal Items||-1.483M|
|Cash and Cash Equivalents||1.037M|
|Price/Gross Cash Flow||-94.72|
|Dividend Yield Excluding Special||0.00%|
|Gross DPS (AUD)||0|
|Gross Dividend Yield (Annualized)||0.00%|
|Net Tangible Asset (NTA)||0.00|
|Net Profit Margin (%)||-63.65%|
|Gross Cash Flows Per Share||-0.00|
|Sales Per Share||0.00|
|Book Value Per Share||0.00|
Australian life sciences firm Invion Limited (ASX:IVX) is focused on transforming Photodynamic Therapy (PDT) to develop pioneering and effective cancer therapies.
PDT is an established treatment that enhances the utilisation of non-toxic photosensitisers as well as visible light for destroying cancer cells and invigorating the immune system. Invion is engaged in developing more effective, next-generation PDT that overcomes the multiple shortcomings of the existing PDT therapies.
Invion is a global leader in the R&D of Photosoft™ technology. The Company has the license as well as distribution rights to the Photosoft™ technology in Australia and New Zealand.
IVX has developed a new intravenous (IV) and topically administered product appropriate for solid tumours (prostate, ovarian, and lung cancer) and skin cancer.
Invion has signed an agreement with RMW Cho Group Limited for the clinical development of PhotosoftTM technology across the globe. RMW Cho also offers non-dilutive funding to Invion for the research and clinical trials of the PhotosoftTM Technology through an R&D services agreement.
The Company has partnered with world-leading medical research institutes for developing a novel photosensitiser named IVX-PDT. Invion is confident that this novel photosensitiser will improve the treatment of challenging solid cancers and skin cancers. The objective of developing IVX-PDT is to be more efficient in targeting and destroying cancer cells with no harmful side effects and negligible discomfort.
With a substantial clinical and commercial potential of its assets, Invion is advancing multiple programs and initiate pre-clinical and clinical studies in partnership with Hudson Institute of Medical Research and The Peter MacCallum Cancer Centre.
IVX and its research partners are targeting cancers, including topical indications for Actinic Keratosis and Basal Cell Carcinoma as well as intravenous indications for mesothelioma, rare cancer associated with asbestos exposure.
Level 4, 100 Albert Road, SOUTH MELBOURNE, VIC, AUSTRALIA, 3205
|Ex-Date||Net Dividend||Frank Flag||Period End Date||Type||Payable|
|Event Type||Event Date||Event Year|